Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 8/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23005915 | 1.00 | CFTR (0.54) | CFTRHTR2APDE4DSCN5AMAP2K1 | |
| SCHEMBL19027867 | 0.87 | CFTR (0.55) | CFTRHTR2APDE4DSCN5AMAP2K1 | |
| SCHEMBL29592296 | 0.81 | CFTR (0.59) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL19412365 | 0.81 | CFTR (0.59) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL10034147 | 0.80 | CFTR (0.48) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL10066236 | 0.80 | CFTR (0.48) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL14952113 | 0.78 | CFTR (0.47) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL19651573 | 0.77 | CFTR (0.62) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL17793903 | 0.77 | CFTR (0.48) | CFTRHTR2APDE4DSCN5A | |
| SCHEMBL19656711 | 0.76 | CFTR (0.54) | CFTRHTR2APDE4DSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224931-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2021176064-A1 | SOLID FORMS OF TEZACAFTOR AND PROCESSES FOR THE PREPARATION THEREOF | Química Sintética, S.A. (ES) | 2021-09-10 | — | — | WO | disclosed |